CN102688311A - Traditional Chinese medicine compound preparation with blood pressure reducing function and preparation method thereof - Google Patents
Traditional Chinese medicine compound preparation with blood pressure reducing function and preparation method thereof Download PDFInfo
- Publication number
- CN102688311A CN102688311A CN2012102113861A CN201210211386A CN102688311A CN 102688311 A CN102688311 A CN 102688311A CN 2012102113861 A CN2012102113861 A CN 2012102113861A CN 201210211386 A CN201210211386 A CN 201210211386A CN 102688311 A CN102688311 A CN 102688311A
- Authority
- CN
- China
- Prior art keywords
- preparation
- parts
- traditional chinese
- fructus
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine compound preparation with a blood pressure reducing function and a preparation method thereof. The traditional Chinese medicine compound preparation mainly consists of radix salviae miltiorrhizae, semen cassiae, radix achyranthis bidentatae, earthworm, fructus rosae laevigatae, tribulus terrestris, fructus aristolochiae and spica prunellae. The preparation method comprises the following steps of: compounding the traditional Chinese medicines, and adding water to decoct; taking and concentrating the supernatant; performing spray drying to obtain the extract; and adding the pharmaceutically acceptable auxiliaries into the extract to obtain an oral preparation. In the invention, the compatibility of medicines is scientific, the preparation technology is reasonable, and the active ingredients of the traditional Chinese medicine raw materials are not damaged; and the traditional Chinese medicine compound preparation has the functions of dredging blood vessels and reducing blood pressure, does not cause obvious influence on the heart, ensures little change of the heart rate in the case of reduction of blood pressure, and has a perfect market prospect.
Description
Technical field
The present invention provides a kind of compound Chinese medicinal preparation with hypotensive activity, and the method for preparing of above-mentioned compound oral agent also is provided simultaneously, belongs to traditional Chinese medical science pharmaceutical technology field.
Technical background
At present, the cardiovascular disease due to the vascular hypertension is one of current principal disease that jeopardizes human health and life, and the hypertension study on prevention that U.S. hypertension academy carried out 7 years confirms: the application of Altace Ramipril can reduce heart and brain mortality rate 25%; Reduce non-lethality heart attack rate 20%; At present, though Western medicine has hypotensive activity, prolonged application has untoward reaction more; Therefore; Through research, find out a kind of safe, reliable and effective Altace Ramipril and just seem extremely important, but existing antihypertensive drugs majority does not reach the function of comprehensive coordination treatment, treating both the principal and secondary aspects of a disease Chinese medicine.
Summary of the invention
The invention provides a kind of compound Chinese medicinal preparation, can effectively reduce blood pressure with hypotensive activity.
The present invention also provides the preparation technology of the compound Chinese medicinal preparation with hypotensive activity, is applicable to suitability for industrialized production.
A kind of Chinese medicine preparation disclosed by the invention with hypotensive activity,It is characterized in that by following raw materials by weight portion than processing:
Radix Salviae Miltiorrhizae 10-12 part, Semen Cassiae 8-11 part, Radix Achyranthis Bidentatae 8-10 part, Pheretima 6-8 part, Fructus Rosae Laevigatae 6-8 part, Fructus Tribuli 4-7 part, Fructus Aristolochiae 2-5 part, Spica Prunellae 2-5 part;
Compound Chinese medicinal preparation with hypotensive activity of the present invention is characterized in that optimum ratio is:
12 parts of Radix Salviae Miltiorrhizae, 11 parts of Semen Cassiaes, 10 parts of Radix Achyranthis Bidentataes, 8 parts of Pheretimas, 6 parts of Fructus Rosae Laevigatae, 4 parts of Fructus Tribulis, 2 parts of Fructus Aristolochiaes, 2 parts of Spica Prunellaes.
Method for preparing with Chinese medicine compound oral formulations of hypotensive activity according to the invention is characterized in that may further comprise the steps:
Take by weighing above-mentioned raw materials in proportion, extracting in water 1 ~ 3 time, the water of each adding are 8 ~ 10 (w/v) times of total medical material amount, and extraction time is 1 ~ 2 hour; Merge extractive liquid, is concentrated into 20% ~ 30% of original volume, and spray drying gets extract.
The said extracted thing is mixed with medically acceptable adjuvant, press the relevant requirements in the Pharmacopoeia of People's Republic of China 2010 editions, process peroral dosage forms such as tablet, capsule, granule.The UD of these oral formulations generally comprises this extract of 10 ~ 1000mg.
Good effect of the present invention is:Process preparation for pure Chinese herbal medicine extract, have mediation blood vessels, blood pressure lowering, sustain losses in business and set upright, transfer the ability that body self is regulated; Tangible hypotensive activity is arranged, heart is not had obvious influence, and few side effects, preparation technology is simple; Taking dose is little, and taking convenience is easy to carry and preserves.
The specific embodiment:
For the ease of understanding the present invention, special case is lifted following examples.Its effect is understood that it is to explaination of the present invention but not to any type of restriction of the present invention.
Embodiment 1
Compound extract in this enforcement, medical material consists of: Radix Salviae Miltiorrhizae 12g, Semen Cassiae 11g, Radix Achyranthis Bidentatae 10g, Pheretima 8g, Fructus Rosae Laevigatae 6g, Fructus Tribuli 4g, Fructus Aristolochiae 2g, Spica Prunellae 2g.
Above-mentioned medical material is mixed, add the water of 10 times of weight, boil and extract 3 times, each 1.5h, merge extractive liquid, is concentrated into 20% of original volume, and spray drying gets extract.
Embodiment 2
Compound extract in this enforcement, medical material consists of: Radix Salviae Miltiorrhizae 10g, Semen Cassiae 8g, Radix Achyranthis Bidentatae 8g, Pheretima 8g, Fructus Rosae Laevigatae 7g, Fructus Tribuli 7g, Fructus Aristolochiae 5g, Spica Prunellae 5g.
Above-mentioned medical material is mixed, add the water of 6 times of weight, boil and extract 2 times, each 2h, merge extractive liquid, is concentrated into 30% of original volume, and spray drying gets extract.
Embodiment 3
Compound extract in this enforcement, medical material consists of: Radix Salviae Miltiorrhizae 12g, Semen Cassiae 1g, Radix Achyranthis Bidentatae 8g, Pheretima 6g, Fructus Rosae Laevigatae 8g, Fructus Tribuli 6g, Fructus Aristolochiae 5g, Spica Prunellae 5g.
Above-mentioned medical material is mixed, add the water of 8 times of weight, boil and extract 1 time, each 3h collects extracting solution, is concentrated into 30% of original volume, and spray drying gets extract.
Embodiment 4
Take by weighing the compound extract of embodiment 1 or embodiment 2 or embodiment 3 preparations: 1 weight portion
Starch, dextrin mixture: 1 weight portion
Get above-mentioned compound extract dry powder, the adjuvant of weight such as adding is as excipient, and mix homogeneously gets mixed-powder; Add 95% ethanol and make soft material, 16～20 mesh sieves are granulated, 70 ~ 80 ℃ of dryings of wet granular 30 minutes, and 16～20 mesh sieve granulate, tabletting promptly gets.Sundry item should meet 2010 editions tablet projects of Pharmacopoeia of People's Republic of China relevant requirements.
Embodiment 5
Take by weighing the compound extract of embodiment 1 or embodiment 2 or embodiment 3 preparations: 1 weight portion
Starch: 1.5 weight portions
Get Armadillidium, Rhizoma Corydalis, Radix Cynanchi Paniculati compound extract, the starch that adds 1.5 times of weight is as excipient, and mix homogeneously adds wetting agent or binding agent system soft material, granulate, and 70 ~ 80 ℃ of dryings 30 minutes, granulate, the fill capsule is packed and is promptly got.Sundry item should meet 2010 editions capsule projects of Pharmacopoeia of People's Republic of China relevant requirements.
Embodiment 6
Take by weighing the compound extract of embodiment 1 or embodiment 2 or embodiment 3 preparations: 1 weight portion
Icing Sugar: 1 weight portion
Starch: 0.5 weight portion
Get Armadillidium, Rhizoma Corydalis, Radix Cynanchi Paniculati, the Radix Angelicae Dahuricae, Radix Linderae extract dry powder, add the Icing Sugar of 1 times of weight and the starch of 0.5 times of weight, mix homogeneously; Add 65% ethanol system soft material, 16 mesh sieves are granulated, 70 ~ 80 ℃ of dryings of wet granular 30 minutes; 16～30 mesh sieves choosing grain, mix homogeneously, fill promptly gets.Sundry item should meet 2010 editions granule projects of Pharmacopoeia of People's Republic of China relevant requirements.
The situation of clinical drug observation of curative effect of the present invention is following:
Essential hypertension people 300 examples, male 140 examples, women 160 examples, at 45 ~ 61 years old age, blood pressure is (160 ~ 200)/(95 ~ 114) mmHg, hematuria is conventional, renal function is normal.Adopt method at random to be divided into four groups, stop using other 2 weeks of depressor before every group 75 routine patient (male 35 examples, women 40 examples): embodiment 4 (tablet) group, embodiment 5 (capsule) group, embodiment 6 (granule) group and matched group (indapamide sheet) random packet by sex, age and blood pressure pairing; Take placebo between withdrawal time; 1 of every day, early take after the meal, as the introduction period; First all outpatient services are followed up a case by regular visits to 1 time; Second all outpatient services are followed up a case by regular visits to 2 times, survey right arm seat blood pressure 3 times, get diastolic pressure wherein differ be no more than 4 mmHg 2 meansigma methodss as treatment before basic blood pressure.
Medication: 4 groups of experimental examples (tablet), every day 2 times, each 3, every 0.5g; 5 groups of embodiment (capsule), every day 2 times, each 3, every 0.5g; 6 groups of embodiment (granule), every day 2 times, each 1.5g.Matched group is given the indapamide sheet, each 2.5mg, every day 1 time, 12 weeks of the course of treatment.
Blood pressure such as table 1 before and after two groups of treatments:
Blood pressure before and after the table 1 liang group treatment
| Group | N | Systolic pressure (mmHg) | Diastolic pressure (mmHg) |
| Before 4 groups of medications of experimental example | 75 | 170.6±18.1 | 100.6±9.1 |
| 3 weeks after 4 groups of medications of experimental example | 75 | 155.3±17.3 | 97.2±9.0 |
| 6 weeks after 4 groups of medications of experimental example | 75 | 146.0±16.5 | 94.8±9.3 |
| 12 weeks after 4 groups of medications of experimental example | 75 | 143.8±17.5 | 90.6±8.3 |
| Before 5 groups of medications of embodiment | 75 | 171.1±18.6 | 101.1±9.6 |
| 3 weeks after 5 groups of medications of embodiment | 75 | 155.8±16.8 | 97.7±9.9 |
| 6 weeks after 5 groups of medications of embodiment | 75 | 146.5±15.6 | 95.3±9.7 |
| 12 weeks after 5 groups of medications of embodiment | 75 | 144.9±17.2 | 91.9±8.3 |
| Before 6 groups of medications of embodiment | 75 | 170.1±17.1 | 100.1±11.4 |
| 3 weeks after 6 groups of medications of embodiment | 75 | 154.8±17.9 | 96.7±12.3 |
| 6 weeks after 6 groups of medications of embodiment | 75 | 145.5±16.0 | 94.3±11.0 |
| 12 weeks after 6 groups of medications of embodiment | 75 | 143.1±17.0 | 89.9±8.9 |
| Before the matched group medication | 75 | 168.4±16.4 | 100.1±8.6 |
| 3 weeks after the matched group medication | 75 | 149.7±17.1 | 96.2±8.9 |
| 6 weeks after the matched group medication | 75 | 143.9±17.6 | 92.9±9.2 |
| 12 weeks after the matched group medication | 75 | 141.4±18.1 | 88.9±9.7 |
Two groups of efficacy of antihypertensive treatment are relatively like table 2:
The table 2 liang group medicine efficacy of antihypertensive treatment rate of exchange
| Group | N | Significantly | Effectively | Invalid | Total effective rate |
| 4 groups of experimental examples | 75 | 37 | 25 | 13 | 82.67% |
| 5 groups of embodiment | 75 | 38 | 23 | 14 | 81.33% |
| 6 groups of embodiment | 75 | 36 | 25 | 14 | 81.33% |
| Matched group | 75 | 35 | 20 | 20 | 73.33 |
The therapeutic evaluation standard is 1. remarkable: diastolic pressure descends>10mmHg, and reduce to normal range ≦ 90mmHg), or shrink drops ≧ 20mmHg; 2. effective: diastole drops ≦ 10 mmHg, but reduce to normal range, or diastolic pressure decline 10 ~ 19 mmHg, or shrink drops ≧ 30 mmHg; 3. invalid: blood pressure drops does not reach effective standard.
Conclusion: embodiment 4 (tablet) group, embodiment 5 (capsule) group, embodiment 6 (granule) 3 weeks of treatment, 6 weeks and 12 all after-contraction pressures and diastolic pressure are all than significantly reducing before the medication; The present invention is a kind of safe and effective depressor; Can supply clinical prolonged application, especially be suitable for some light moderate essential hypertension patients.
Claims (3)
1. compound Chinese medicinal preparation with hypotensive activity is characterized in that by following raw materials by weight portion than processing:
Radix Salviae Miltiorrhizae 10-12 part, Semen Cassiae 8-11 part, Radix Achyranthis Bidentatae 8-10 part, Pheretima 6-8 part, Fructus Rosae Laevigatae 6-8 part, Fructus Tribuli 4-7 part, Fructus Aristolochiae 2-5 part, Spica Prunellae 2-5 part.
2. the compound Chinese medicinal preparation with hypotensive activity as claimed in claim 1 is characterized in that optimum ratio is:
12 parts of Radix Salviae Miltiorrhizae, 11 parts of Semen Cassiaes, 10 parts of Radix Achyranthis Bidentataes, 8 parts of Pheretimas, 6 parts of Fructus Rosae Laevigatae, 4 parts of Fructus Tribulis, 2 parts of Fructus Aristolochiaes, 2 parts of Spica Prunellaes.
3. have the method for preparing of the compound Chinese medicinal preparation of hypotensive activity according to claim 1 or claim 2, it is characterized in that may further comprise the steps:
Take by weighing above-mentioned raw materials in proportion, extracting in water 1 ~ 3 time, the water of each adding are 8 ~ 10 (w/v) times of total medical material amount, and extraction time is 1 ~ 2 hour; Merge extractive liquid, is concentrated into 20% ~ 30% of original volume, and spray drying gets extract; Extract is mixed with medically acceptable adjuvant, press the relevant requirements in the Pharmacopoeia of People's Republic of China 2010 editions, process peroral dosage forms such as tablet, capsule, granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102113861A CN102688311A (en) | 2012-06-26 | 2012-06-26 | Traditional Chinese medicine compound preparation with blood pressure reducing function and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012102113861A CN102688311A (en) | 2012-06-26 | 2012-06-26 | Traditional Chinese medicine compound preparation with blood pressure reducing function and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102688311A true CN102688311A (en) | 2012-09-26 |
Family
ID=46854155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012102113861A Pending CN102688311A (en) | 2012-06-26 | 2012-06-26 | Traditional Chinese medicine compound preparation with blood pressure reducing function and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102688311A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104666488A (en) * | 2015-02-04 | 2015-06-03 | 邱杨清 | Blood-circulation-promoting and blood pressure-reducing traditional Chinese medicine composition using saussurea involucrate and preparation method of composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1388344A1 (en) * | 2002-07-31 | 2004-02-11 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Composition comprising Salvia Miltiorrhizae, Ginseng, Borneol for treating heart disease, and cerebrovascular diseases |
| CN1657085A (en) * | 2004-09-06 | 2005-08-24 | 青岛国风药业股份有限公司 | Oral Chinese medicinal composition for treating hypertension |
| WO2010053456A1 (en) * | 2008-11-10 | 2010-05-14 | Moleac Pte. Ltd. | Combination therapy for treatment of patients with neurological disorders and cerebral infarction |
-
2012
- 2012-06-26 CN CN2012102113861A patent/CN102688311A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1388344A1 (en) * | 2002-07-31 | 2004-02-11 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Composition comprising Salvia Miltiorrhizae, Ginseng, Borneol for treating heart disease, and cerebrovascular diseases |
| CN1657085A (en) * | 2004-09-06 | 2005-08-24 | 青岛国风药业股份有限公司 | Oral Chinese medicinal composition for treating hypertension |
| WO2010053456A1 (en) * | 2008-11-10 | 2010-05-14 | Moleac Pte. Ltd. | Combination therapy for treatment of patients with neurological disorders and cerebral infarction |
Non-Patent Citations (1)
| Title |
|---|
| 王振国等，: "《心病实用方》", 31 July 1999, article "八味降压汤", pages: 421 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104666488A (en) * | 2015-02-04 | 2015-06-03 | 邱杨清 | Blood-circulation-promoting and blood pressure-reducing traditional Chinese medicine composition using saussurea involucrate and preparation method of composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101584797B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
| CN101607006B (en) | Application of Chinese medicinal composition in preparing medicament for treating hypertension | |
| CN104547826A (en) | Medical application of galangin extract to treat dysmenorrhea | |
| CN102028827A (en) | Medicinal composition for treating urinary tract infection and preparation method thereof | |
| CN102940800A (en) | Traditional Chinese medicine for treating diabetes | |
| CN102688311A (en) | Traditional Chinese medicine compound preparation with blood pressure reducing function and preparation method thereof | |
| CN102641357B (en) | Medicament for treating hypertension and preparation method thereof | |
| CN101653550B (en) | Chinese medicinal composition in preparation of medicament for treating type II diabetes | |
| CN101904935A (en) | Chinese medicinal composition for improving immunity of organisms, tonifying middle-jiao and qi and treating canine distemper | |
| CN101745048B (en) | Medicine for treating type II diabetes and resisting aging | |
| CN101167951A (en) | Traditional Chinese medicinal composition for treating diabetes and its preparation method | |
| CN101194945B (en) | Tablet for treating headache and method for preparing the same | |
| CN102068674A (en) | Chinese medicinal composition for treating chronic diarrhea and preparation method thereof | |
| CN101618156A (en) | Medicine composition for treating hepatitis B and preparation method thereof | |
| CN102205031B (en) | Traditional Chinese medicine for treating male sterility | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
| CN102430040A (en) | Medicament for treating diabetes | |
| CN104027450B (en) | A kind of Chinese medicine composition for the treatment of diabetes | |
| CN102552679A (en) | Medicine for treating vital myocarditis | |
| CN102973906A (en) | Weiyangling and preparation method thereof | |
| CN102247515A (en) | Traditional Chinese medicine compound preparation used for treating diabetic nephropathy, and preparation method thereof | |
| CN101194958B (en) | Method for preparing decocted ointment for treating headache | |
| CN101628102A (en) | Medicament for preventing and treating fatty liver and preparation process thereof | |
| KR100601823B1 (en) | Pharmaceutical composition for human immunodificiency virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120926 |